TransThera Sciences (Nanjing), Inc. (HKG:2617)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
47.66
-0.90 (-1.85%)
May 7, 2026, 4:08 PM HKT
Market Cap19.62B
Revenue (ttm)n/a
Net Income-329.35M
EPS-0.85
Shares Out404.08M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,184,500
Average Volume1,058,421
Open49.82
Previous Close48.56
Day's Range47.22 - 49.82
52-Week Range20.20 - 679.50
Betan/a
RSI23.30
Earnings DateMay 22, 2026

About HKG:2617

TransThera Sciences (Nanjing), Inc., clinical stage biopharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (TT-00420), a MTK inhibitor that is in clinical stage for the treatment of recurrent or refractory drug-resistant solid tumors. It also develops TT-00973, a kinase inhibitor for treating various cancers; TT-01488, a BTK inhibitor for the treatment of B-cell lymphoma; TT-01688, an oral S1P1 modulator for treating ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 121
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2617
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements